Biogen (NASDAQ:BIIB) Given New $275.00 Price Target at Oppenheimer

Biogen (NASDAQ:BIIB) had its price target boosted by Oppenheimer from $250.00 to $275.00 in a research note published on Wednesday, MarketBeat.com reports. They currently have an outperform rating on the biotechnology company’s stock.

BIIB has been the topic of several other reports. Morgan Stanley set a $190.00 price objective on Biogen in a report on Sunday, February 8th. Wolfe Research set a $231.00 price target on Biogen in a research report on Monday, February 9th. Royal Bank Of Canada raised their price target on Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a research note on Monday, February 9th. Wedbush lifted their price objective on Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a report on Monday, February 9th. Finally, BMO Capital Markets upped their price objective on shares of Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a research note on Friday, February 6th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Biogen presently has a consensus rating of “Hold” and a consensus target price of $207.96.

Biogen Price Performance

Shares of BIIB stock opened at $183.78 on Wednesday. The company has a market capitalization of $26.97 billion, a P/E ratio of 20.86, a P/E/G ratio of 1.46 and a beta of 0.16. The company’s 50-day simple moving average is $186.41 and its two-hundred day simple moving average is $171.07. Biogen has a one year low of $110.04 and a one year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s revenue was down 7.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, equities analysts anticipate that Biogen will post 15.83 EPS for the current year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Elevation Point Wealth Partners LLC purchased a new stake in shares of Biogen during the 2nd quarter worth $25,000. Reflection Asset Management bought a new stake in Biogen during the fourth quarter valued at about $25,000. WPG Advisers LLC grew its stake in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 117 shares during the last quarter. Accredited Wealth Management LLC raised its holdings in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 185 shares in the last quarter. Finally, First Horizon Corp bought a new position in Biogen in the fourth quarter worth about $30,000. 87.93% of the stock is owned by institutional investors.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen agreed to acquire Apellis for about $5.6 billion in cash, bringing two commercial immunology/rare‑disease drugs (SYFOVRE®, EMPAVELI®) and a nephrology launch capability — expected to boost near‑term revenue and diversify Biogen beyond MS. Biogen to buy Apellis Pharmaceuticals for $5.6 billion (Reuters)
• Positive Sentiment: Analysts reacted with higher price targets and constructive coverage: Oppenheimer raised its PT to $275 (outperform) and Canaccord to $245 (buy), lifting sentiment that the deal and other pipeline wins improve Biogen’s growth profile. Oppenheimer raises Biogen price target (MarketScreener)
• Positive Sentiment: FDA approval of a higher‑dose SPINRAZA regimen supports Biogen’s rare‑disease revenues and reduces competitive risk in SMA, adding another near‑term commercial tailwind alongside Apellis assets. Biogen secures FDA nod for higher‑dose SPINRAZA (Zacks)
• Neutral Sentiment: Biogen management says combined cash flow from Biogen + Apellis should improve leverage ratios and free capacity for further deals — management framing the purchase as strategic rather than one‑off. Biogen CFO comments on cash flow and M&A capacity (BioPharmaDive)
• Neutral Sentiment: Apellis shares surged (more than doubled) on the takeover premium; that rally reflects deal certainty for Apellis but only partially signals upside for Biogen beyond the strategic rationale. Apellis hits multi‑year high on Biogen deal (Yahoo Finance)
• Negative Sentiment: An investor law firm has opened an investigation into the adequacy of the Apellis sale price/process, which could signal proxy litigation or shareholder pushback that complicates or delays closing. Investor investigation into Apellis sale process (BusinessWire)
• Negative Sentiment: Some analysts remain cautious (Hold ratings cited), pointing to execution risk on Leqembi/ MS erosion, integration risk and the cash outflow’s near‑term impact — these concerns help explain any initial pressure on Biogen shares after the deal news. Analyst caution/hold ratings despite positives (TipRanks)

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.